ReviewDiscover oncology2026
Artesunate nanoliposomes in hepatocellular carcinoma: mechanistic ferroptosis induction and translational opportunities.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Artesunate nanoliposomes are lipid-based nanoscale vesicles encapsulating the antimalarial agent artesunate, which have shown potential to suppress hepatocellular carcinoma (HCC) growth and metastasis by modulating ferroptosis-related pathways. This review first summarizes the preparation methods and physicochemical characteristics of artesunate nanoliposomes, followed by an overview of the ferroptosis pathways through which artesunate induces cell death in HCC. We then integrate existing studies to clarify how artesunate nanoliposomes suppress HCC progression via ferroptosis regulation. Finally, we discuss their clinical prospects, associated challenges, and future research directions. Overall, this review aims to elucidate the mechanistic basis of artesunate's antitumor effects, providing insights for identifying novel therapeutic targets and advancing the development of ferroptosis-based treatments for liver cancer.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.